AAV9 vector expressing human beta-galactosidase
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AAV9 vector expressing human beta-galactosidase, covering 2025-12-11 to 2025-12-11. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis [Phase 1, Phase 2]